ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2116

Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data

Lisa Lindsay1, Ching-Yi Chuo 2, Nicholas Jones 2, Joshua Galanter 2, Anna McGregor 2 and Katie Tuckwell 2, 1Genentech Inc, SOUTH SAN FRANCISCO, CA, 2Genentech Inc, SOUTH SAN FRANCISCO

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus nephritis, rheumatoid arthritis (RA) and infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact of the disease itself and treatments that modulate immune function. Rates of SIs resulting in hospitalization among these patients have not been compared to the general population. The objective of this study was to compare the rates of SIs resulting in an inpatient claim in adult patients with SLE/LN, RA and the general population using population-based claims data.

Methods: We conducted a retrospective cohort study using the US-based Truven Healthcare MarketScan® Claims database for individuals aged 18-64 years enrolled between January 2007 and September 2015. Patients were required to have continuous enrollment for ≥ 90 days pre- and ≥ 365 days post-index date. Patients with SLE/LN (including non-renal SLE and LN) and RA were identified using modifications to algorithms developed for use in registry and/or claims data. The general population included individuals without SLE/LN or RA. Index date for the SLE/LN and RA cohorts was the date when patients fulfilled the diagnostic algorithms for SLE/LN, or RA. Index date for the general population occurred after 90 days of continuous enrollment. Patients were excluded from all cohorts if they had: an auto-immune (AI) condition other than SLE/LN or RA; cancer; received a solid-organ transplant; or HIV/AIDs. First incident SIs were identified as those that resulted in an inpatient claim for a pre-specified set of ICD-9 codes within 365 days of index date. Incidence rates (IRs) and standardized incidence ratios (SIRs) were calculated along with 95% confidence intervals (CI) adjusted for age, gender, index year, prevalent SI and glucocorticoid use.

Results: The SLE/LN, RA, and general population cohorts included 58,105, 183,229, and 50,530,269 patients, respectively. Table 1 provides a summary of cohort-specific patient characteristics. As anticipated, the SLE/LN and RA cohorts were predominantly female. The RA cohort was generally older than the other cohorts. Index date was fairly consistent across study year and cohort. In all cohorts, the unadjusted SI IRs increased with age, were higher among patients who had a prior SI (claim ≤ 90 days prior to the index date), and were slightly increased in patients who received systemic glucocorticoids ≤ 365 days after their index date. Adjusted SI IRs (95% CIs) were 21.2 (21.1, 21.2) in SLE/LN patients, followed by 15.8 (15.8, 15.8) in RA patients, and 3.8 (3.7, 3.8) in the general population (Table 2). Adjusted SIRs were 4.4 and 2.8 times higher among patients with SLE/LN and RA compared to the general population, respectively.  

Conclusion: In this population-based analysis of claims data, adjusted SI IRs were highest in SLE/LN patients. Both AI cohorts experienced excess SI rates compared to the general population. These rates were based on inpatient claims from patients with varying disease severity and treatment patterns. Further characterization of the role of treatment and type of infection is warranted. Findings demonstrate the important contribution of SIs on the burden of disease among SLE/LN and RA patients.


Serious Infection in Patients with SLE, LN, RA and Gen Pop Table 1

Description of study population.


Serious Infection in Patients with SLE, LN, RA and Gen Pop Table 2

Adjusted incidence rate -IR- and standardized incidence ratios -SIR- -95% confidence interval- for serious infections -SIs- for individuals with systemic lupus erythematosus-SLE-/lupus nephritis -LN-, rheumatoid arthritis -RA- and the general population.


Disclosure: L. Lindsay, Genentech, Inc., 3, 4; C. Chuo, Genentech, Inc., 3, 4; N. Jones, Genentech, 1, 3; J. Galanter, Genentech, a member of the Roche Group, 1, 3; A. McGregor, Genentech, Inc., 3; K. Tuckwell, Genentech, Inc., 3, 4.

To cite this abstract in AMA style:

Lindsay L, Chuo C, Jones N, Galanter J, McGregor A, Tuckwell K. Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/serious-infection-in-patients-with-systemic-lupus-erythematosus-lupus-nephritis-and-rheumatoid-arthritis-compared-to-the-general-population-incidence-rates-using-real-world-claims-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serious-infection-in-patients-with-systemic-lupus-erythematosus-lupus-nephritis-and-rheumatoid-arthritis-compared-to-the-general-population-incidence-rates-using-real-world-claims-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology